Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The ocular surface mucin and glycoprotein layer is a complex, hydrated gel-like structure essential for maintaining the health and integrity of the cornea and conjunctiva (Gipson, 2004). It consists of membrane-associated mucins (MUC1, MUC4, MUC16) that form the glycocalyx and secreted mucins (primarily MUC5AC) that are dispersed within the aqueous layer of the tear film (Mantelli & Argüeso, 2008). Its primary biological function is to provide a hydrophilic interface that allows the aqueous tears to spread evenly across the hydrophobic ocular surface, ensuring lubrication and preventing desiccation (Dartt, 2004). Additionally, this layer acts as a physical and chemical barrier against mechanical friction, pathogens, and environmental toxins (Gipson, 2004). Dysregulation or deficiency of these mucins is a hallmark of dry eye disease and Sjögren's syndrome, leading to tear film instability and epithelial damage (Mantelli & Argüeso, 2008). Pharmacological interventions include mucin secretagogues such as Diquafosol, which acts on P2Y2 receptors to stimulate secretion, and Rebamipide, which increases mucin expression to restore the ocular surface barrier (Uchino et al., 2011). Mucin-mimetic agents like hydroxypropyl guar are also used to supplement the natural layer and improve tear film stability (Gipson, 2004). Understanding the molecular composition of this layer is crucial for developing targeted therapies for various ocular surface disorders.
Mucin secretagogue (P2Y2 receptor agonism), induction of mucin gene expression (MUC1, MUC4, MUC16), mucin stabilization, and mucin-mimetic lubrication.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ocular surface mucin and glycoprotein layer.